10-Q: QuidelOrtho Reports Q3 Loss Amid Goodwill Impairment, Restructuring

QuidelOrtho Corporation reported a significant net loss in the third quarter of 2025, primarily driven by a $700.7 million goodwill impairment charge and ongoing restructuring efforts.

Summary

• Net loss for the three months ended September 28, 2025, was $733.0 million, a substantial increase from a net loss of $19.9 million in the prior year period.
• For the nine months ended September 28, 2025, the net loss was $1,001.1 million, an improvement from $1,873.6 million in the prior year, but still a significant loss.
• Total revenues decreased by 4% to $699.9 million for the three months and by 3% to $2,006.6 million for the nine months ended September 28, 2025, compared to the respective prior year periods.
• A non-cash goodwill impairment charge of $700.7 million was recorded in the third quarter of 2025, fully impairing the goodwill allocated to the EMEA, China, and Latin America reporting units.
• The company launched a multi-year Optimization Plan in Q2 2025, aiming for approximately $50 million in net cost savings through 2027, with expected cumulative pre-tax charges of $100 million.
• Strategic refocusing of the Molecular Diagnostics business includes discontinuing the development of the Savanna platform, expected to be substantially complete by the first half of 2027, and an intent to acquire LEX Diagnostics.
• Disclosure controls and procedures were deemed not effective as of September 28, 2025, due to previously reported material weaknesses in internal control over financial reporting.
• Debt was refinanced on August 21, 2025, through a new Credit Agreement providing $2.7 billion in Term Loans and a $700 million Revolving Credit Facility, used to repay previous debt and incurring a $5.1 million loss on extinguishment.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a substantial net loss, a significant goodwill impairment charge, overall revenue decline, and the disclosure of ineffective internal controls. While there are strategic initiatives for cost savings and growth in specific segments, the immediate financial performance and governance concerns outweigh these positives.

Positives

• Labs revenue increased 5% for both the three months ($373.8 million) and nine months ($1,116.5 million) ended September 28, 2025, compared to prior year periods.
• Immunohematology revenue increased 8% to $142.0 million for the three months and 4% to $402.8 million for the nine months ended September 28, 2025.
• Research and development expenses decreased by 25.8% to $41.5 million for the three months and by 18.1% to $140.4 million for the nine months ended September 28, 2025, primarily due to lower clinical costs.
• Selling, marketing and administrative expenses decreased by 4.7% to $551.9 million for the nine months ended September 28, 2025, driven by lower compensation and outside services.
• The Optimization Plan is expected to deliver approximately $50 million in net cost savings through 2027.
• Successfully refinanced debt with a new Credit Agreement, maintaining compliance with financial covenants as of September 28, 2025.

Negatives

• Net loss significantly widened to $733.0 million in Q3 2025 from $19.9 million in Q3 2024.
• Total revenues declined by 4% in Q3 2025 and 3% for the nine months ended September 28, 2025.
• A non-cash goodwill impairment charge of $700.7 million was recorded in Q3 2025, fully impairing goodwill for EMEA, China, and Latin America reporting units.
• Point of Care revenue decreased by 20% in Q3 2025 and 16% for the nine months, primarily due to lower sales of QuickVue and Sofia SARS Antigen assays.
• Donor Screening revenue decreased by 47% in Q3 2025 and 57% for the nine months due to the planned wind-down of the U.S. donor screening business.
• Restructuring, integration and other charges increased to $39.6 million in Q3 2025 and $234.6 million for the nine months.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.
• Interest expense, net, increased to $46.1 million in Q3 2025 and $126.6 million for the nine months.
• A $5.1 million loss on extinguishment of debt was recognized in connection with the debt refinancing.

Risks

• Fluctuations in demand for non-respiratory and respiratory products, including COVID-19, flu, strep, and RSV.
• Supply chain, production, logistics, distribution, and labor disruptions and challenges.
• Challenges and costs associated with integrating acquired operations, restructuring initiatives (Optimization Plan), and achieving anticipated synergies.
• Inability to realize the anticipated benefits of acquisitions, debt refinancings, discontinuances of certain business operations (Savanna Exit), or the Optimization Plan.
• Delays in the development of or failures or delays in receiving approvals for new or enhanced products.
• Macroeconomic, geopolitical, market, business, competitive, and regulatory factors, including the effects of announced or future tariffs and trade policies.
• Ongoing legal proceedings, including a class action complaint and stockholder derivative complaints, with uncertain outcomes and potential material adverse effects on the business.
• Material weaknesses in internal control over financial reporting, leading to ineffective disclosure controls and procedures, which could impact financial reporting reliability.

Future Outlook

The company expects continued fluctuations in demand for its non-respiratory and respiratory products, with persistent pricing pressures. Long-term growth and profitability are anticipated to depend on retaining and growing current customers, attracting new customers through developing and delivering new and improved products and services. Management intends to evaluate strategic opportunities to expand product lines, production capabilities, technologies, and geographic footprint, and to rationalize and consolidate facilities. The company plans to increase reagent rental placements in developed and emerging markets to grow its installed base, aiming to increase sales of higher-margin assays and consumables and enhance recurring revenue and cash flows.

Management Comments

• Our vision is to advance diagnostics to power a healthier future.
• We intend to continue our focus on prudently managing our business and delivering improved financial results, while at the same time striving to introduce new products and services into the market.
• We believe that the shift in our sales strategy will grow our installed base, thereby increasing sales of higher-margin assays, reagents and other consumables over the life of the customer contracts and enhancing our recurring revenue and cash flows.

Industry Context

The diagnostics industry faces fluctuating demand for respiratory products, particularly influenced by the seasonality of cold, flu, RSV, and COVID-19 seasons. The competitive environment is intense, leading to pricing pressures on certain products. The company's strategy to increase reagent rental placements aligns with a trend to lower upfront capital costs for customers, potentially expanding market reach. Macroeconomic factors, such as U.S. tariffs on imports from key regions like the U.K., Canada, Mexico, and China, are increasing supply chain costs, a challenge common across global manufacturing industries.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A putative class action complaint, Bristol County Retirement System v. QuidelOrtho Corporation, et al., was filed on April 12, 2024, asserting claims for violations of federal securities laws related to statements regarding COVID-19 diagnostic tests and the Savanna RVP4 assay. An amended complaint was filed on February 7, 2025, and defendants filed a motion to dismiss on April 4, 2025.
• Two stockholder derivative complaints, Matthew Whitfield v. Kenneth F. Buechler, Ph.D., et al. (April 25, 2024) and Steven Pinkney v. Douglas Bryant, et al. (June 21, 2024), were filed, asserting claims for violations of the Exchange Act, breach of fiduciary duty, and other charges. These were consolidated and stayed on December 16, 2024.
• Accrued additional reserves of $9.4 million in Q3 2025 for a contractual dispute with a potential supplier for COVID-19 pandemic raw materials and services, which resulted in a final judgment requiring payment of $10.8 million, paid in Q4 2025.

Stakeholder Impact

• Shareholders: Significant net loss and goodwill impairment could negatively impact share value and investor confidence. Ongoing legal proceedings introduce further uncertainty.
• Employees: The Optimization Plan, focused on cost-reduction and operational efficiencies, may involve workforce reductions or facility rationalization, impacting employment.
• Customers: The planned wind-down of the U.S. donor screening portfolio may affect certain customers, though the company intends to honor contractual commitments. The shift to a reagent rental model aims to lower upfront costs for customers, potentially increasing access to products.
• Creditors: Debt refinancing has altered the company's debt structure, but the company remains in compliance with financial covenants, indicating stability in its ability to meet debt obligations.

Next Steps

• Continue implementation of the multi-year Optimization Plan to achieve cost reductions and margin improvements through 2027.
• Complete the wind-down of the U.S. donor screening portfolio by the first half of 2026.
• Substantially complete the discontinuation of the Savanna platform development by the first half of 2027.
• Proceed with the intent to acquire LEX Diagnostics.
• Continue migrating financial processing systems to SAP over the next several years, updating internal controls as necessary.
• Address and remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company reported a substantial net loss of $733.0 million in Q3 2025, primarily due to a $700.7 million goodwill impairment charge, indicating significant asset value erosion. Overall revenues declined, and disclosure controls were deemed ineffective due to material weaknesses in internal financial reporting. While strategic initiatives like the Optimization Plan and debt refinancing are underway, the immediate financial performance, coupled with ongoing legal challenges and operational risks, presents a highly unfavorable investment profile.

Keywords

Diagnostics, Medical Devices, In Vitro Diagnostics, QDEL, QuidelOrtho, Financial Results, Goodwill Impairment, Restructuring, COVID-19, Respiratory Diagnostics, Point of Care, Labs, Immunohematology, Donor Screening, Molecular Diagnostics, Savanna, LEX Diagnostics, SEC Filing